Loading the company…
Loading the company…
Families: Aneurysm & intracranial embolization, Tumor & fibroid embolization, Carotid revascularization, Thrombectomy, IVC filters & venous stents, BPH procedures.
All companies · Product and company coverage
In the last ten years FDA made 24 decisions for Microvention (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 5 procedure families, the most in 2022 (6). The latest was on 2026-07-07.
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-07-07 | PMA | P210030-S002 | Roadsaver/CASPER Carotid Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-11-02 | PMA | P180027-S013 | Flow Re-Direction Endoluminal Device (FRED®) System · Location Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2025-09-20 | PMA | P180027-S012 | Flow Re-Direction Endoluminal Device (FRED) X System · Postapproval Study Protocol |
| 2025-09-18 | PMA | P180027-S014 | FRED X System · Change Design/Components/Specifications/Material |
In 2025, Microvention reported engagement with 933 surgeons and other clinicians in the states MedaRep covers, worth $2.6M in consulting, speaking, meals and travel for its device products, the most in California ($496K to 131). Royalties are left out.
| 2025-06-23 | PMA | P210030-S001 | Roadsaver/CASPER Carotid Stent Device · Labeling Change - Indications/instructions/shelf life/tradename |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Microvention.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: California ($496K, 131 engaged), New York ($333K, 65 engaged), Minnesota ($248K, 19 engaged), Illinois ($244K, 47 engaged), Florida ($243K, 109 engaged).